AI assistant
Sending…
ARS Pharmaceuticals, Inc. — Director's Dealing 2022
Dec 2, 2022
32159_dirs_2022-12-01_2c4750ca-ba8b-4c5b-a7fe-0e3eb4e7d08c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-12-01
Reporting Person: Fitzpatrick Alexander A (Chief Legal Officer)
More from ARS Pharmaceuticals, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 13
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5